.jpg)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics Inc (NASDAQ: STML) today and set a price target of $38. The company’s shares closed yesterday at $18.45, close to its 52-week high of $18.75.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.5% and a 38.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Stemline Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $38.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.75 and a one-year low of $7.30. Currently, Stemline Therapeutics Inc has an average volume of 283.5K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. It develops a discovery platform called StemScreen, which identifies novel compounds that target and kill cancer stem cells.
